Analyst Price Targets — GLPG
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 24, 2026 7:21 pm | Brian Abrahams | RBC Capital | $33.00 | $34.36 | StreetInsider | Galapagos NV (GLPG) PT Raised to $33 at RBC Capital |
| October 22, 2025 12:22 pm | Brian Abrahams | RBC Capital | $28.00 | $31.43 | TheFly | Galapagos price target raised to $28 from $27 at RBC Capital |
| October 21, 2025 8:08 pm | — | Leerink Partners | $40.00 | $31.43 | TheFly | Galapagos upgraded to Outperform from Market Perform at Leerink |
| July 7, 2021 12:00 am | David Evans | Kepler Capital | $85.92 | $66.78 | Investing | Kepler Capital Stick to Their Hold Rating for Galapagos |
| May 9, 2021 12:00 am | Derek Archila | Wells Fargo | $97.00 | $73.54 | StreetInsider | Galapagos NV (GLPG) PT Raised to $97 at Stifel |
| April 12, 2021 12:00 am | Laura Sutcliffe | UBS | $83.74 | $77.39 | TheFly | Galapagos price target raised to EUR 77 from EUR 75 at UBS |
Latest News for GLPG
Galapagos NV (GLPG) Q1 2026 Earnings Call Transcript
Galapagos' name change to Lakefront Biotherapeutics approved at the Company's EGM (Euronext & NASDAQ: LKFT) Collaboration Agreement with Gilead to advance potential First and Best-in-Class T Cell Engager expected to close in the Second Quarter of 2026 Following this transaction, including estimated associated R&D spend until first approval, the Company will continue to have a majority of its current cash remaining…
Mechelen, Belgium; April 28, 2026, 22:01 CET — Galapagos NV (Euronext & NASDAQ: GLPG) today announces that all resolutions proposed at the Company's Annual and Extraordinary Shareholders' Meetings (AGM and EGM) held on 28 April 2026 were approved.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for GLPG.
Senate Trading
No Senate trades found for GLPG.
U.S. House Trading
No House trades found for GLPG.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.